thought call
jnj good result like receiv attent
think import take-away return growth pharma trough
admittedli jnj oper perform impress even amid modest
expect pharma despit usual season issu donut hole
rebat chang modestli increas fx headwind medic devic
mix consum struggl indic
acceler traction across core franchis oncolog imbruvica darzalex
stelara tremfya rel generic/ biosimilar eros
remicad start moder begin next year talk re-rat
remain justifi given uncertainti time pace jnj line extension/
contract strategi erleada/ spravato/ balversa launch trajectori even
loom mention talc litig overhang continu
encourag path forward toward meaning organ growthand
forecast pharma growth vs prior still
absent insight time maintain ew rate pt
medic devic trend improv consum remain challeng medic devic
sale growth acceler sequenti orthoped also sequenti improv
growth remain modest continu lose share notabl knee
expect growth remain stabl year opportun
acceler year ahead expand robot year-end still
target verb orthotaxi may look acquisit acceler growth
though seem tuck-in may prefer current time consum
growth remain challeng season cite contribut factor
improv near term talc like remain major overhang
model chang follow call updat revenu
forecast respect adjust
ep estim respect
quarterli annual ep usd
return equiti ttm
link barclay live interact chart
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
equal weight continu like jnj
continu innov bode well
longer term sentiment could remain neg
given backdrop price pressures/lo
fundament think could
challeng year particularli pharma given multipl
gener launch zytiga revenu growth
expect trough
could use substanti balanc sheet
acquisit fuel faster expect growth
consum margin could improv quickli
medic devic share growth could acceler
pharmaceut pipelin expect may
conserv
downsid risk includ drug price
pharmaceut pipelin lower expect
clinic commerci success medic devic
util deceler consum margin
expand quickli could result downward
pressur share price
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
geoff meacham ph kristen stewart cfa herebi certifi view express research report accur reflect
person view subject secur issuer refer research report part compens
directli indirectli relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
procedur pleas
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
